CALL/AMGEN/450/0.1/17.01.25 Stock

DE000GQ9GLT8

Real-time BOERSE MUENCHEN 03:04:33 2024-05-29 EDT
0.149 ^EUR	-15.82%

Current month	+142.47%
1 month	+168.18%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart AMGEN INC.

Latest news about AMGEN INC.

US FDA approves Amgen's biosimilar to AstraZeneca's rare blood disorder treatment	05-28	RE
Amgen's Rare-Disease Treatment Biosimilar Bkemv Gets FDA Approval	05-28	DJ
Weight-loss drug forecasts jump to $150 billion as supply grows	05-28	RE
Supreme Court Holds Invalid Cholesterol Drug Patent That Covered Millions Of Undisclosed Antibodies	05-27	AQ

More news

Quotes 5-day view

Date	Price	Change
24-05-29	0.149	-15.82%
24-05-28	0.177	-5.85%
24-05-27	0.188	-2.59%
24-05-24	0.193	+1.05%
24-05-23	0.191	-8.61%

Real-time BOERSE MUENCHEN

Last update May 29, 2024 at 03:04 am

More quotes

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	CALL
Underlying	AMGEN INC.
Issuer	Goldman Sachs
WKN	GQ9GLT
ISIN	DE000GQ9GLT8
Date issued	2024-02-19
Strike	450 $
Maturity	2025-01-17 (234 Days)
Parity	10 : 1
Emission price	0.07 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	0.269 €
Lowest since issue	0.052 €
Spread	0.07 €
Spread %	31.82%

Company Profile

Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows: - drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.; - other (5.8%): primarily royalties. The United States account for 70.3% of net sales.

Sector

More about the company

Ratings for Amgen Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Consensus: Amgen Inc.

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

300.2 USD

Average target price

316.3 USD

Spread / Average Target

+5.36%

Consensus